<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03123692</url>
  </required_header>
  <id_info>
    <org_study_id>Emera003</org_study_id>
    <nct_id>NCT03123692</nct_id>
  </id_info>
  <brief_title>NBMI - Clinical Study on COPD</brief_title>
  <acronym>Emera003COPD</acronym>
  <official_title>A Randomised, Placebo-controlled, Blinded, Cross-over, Pilot Study to Explore Safety and Efficacy of NBMI Treatment of Patients With Mild, Moderate and Severe Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EmeraMed</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EmeraMed</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot study to explore safety of the treatment with the antioxidant and metal chelator NBMI
      in COPD patients.

      Investigational product: NBMI ((N1,N3-bis(2-mercaptoethyl) isophthalamide), INN: Emeramide

      Indication: Mild, moderate and severe COPD with bronchitis

      A randomised, two arm, double-blind, placebo-controlled, cross-over, once daily for 14 days
      pilot study in subjects with COPD with bronchitis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">November 30, 2017</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A randomised, two arm, double-blind, placebo-controlled, cross-over, once daily for 14 days and 28 days follow up</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability - Adverse events</measure>
    <time_frame>14 days</time_frame>
    <description>To evaluate the safety and tolerability of NBMI daily oral administration for 14 days in patients with mild, moderate and severe COPD. Adverse events in terms of frequency and severity compared to placebo treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cough - Changes from baseline in Leicester cough questionnaire compared to placebo treatment</measure>
    <time_frame>14 days</time_frame>
    <description>To investigate the efficacy of NBMI daily oral administration for 14 days on cough in patients with moderate and severe COPD. Changes from baseline in Leicester cough questionnaire compared to placebo treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual symptoms CAT - Changes from baseline in COPD assessment (CAT) test compared to placebo treatment</measure>
    <time_frame>14 days</time_frame>
    <description>To investigate the efficacy of NBMI daily oral administration for 14 days on changes from baseline in COPD assessment (CAT) test compared to placebo treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual symptoms mMRC - Changes from baseline in modified Medical Research Council (mMRC) dyspnoea scale compared to placebo treatment</measure>
    <time_frame>14 days</time_frame>
    <description>To investigate the efficacy of NBMI daily oral administration for 14 days on changes from baseline in in modified Medical Research Council (mMRC) dyspnoea scale compared to placebo treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual symptoms 6 min walking test - Changes from baseline in 6 Minute walk test measurements compared to placebo treatment</measure>
    <time_frame>14 days</time_frame>
    <description>To investigate the efficacy of NBMI daily oral administration for 14 days on changes from baseline in 6 Minute walk test measurements compared to placebo treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual symptoms MDP - Changes from baseline in Multidimensional Dyspnoea Profile (MDP) compared to placebo treatment</measure>
    <time_frame>14 days</time_frame>
    <description>To investigate the efficacy of NBMI daily oral administration for 14 days on changes from baseline in Multidimensional Dyspnoea Profile (MDP) compared to placebo treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory - Changes from baseline of standard haematology and clinical chemistry laboratory analyses (e.g. blood, kidney, liver, infections) compared to placebo treatment</measure>
    <time_frame>14 days</time_frame>
    <description>To investigate the efficacy of NBMI daily oral administration for 14 days on changes from baseline of standard haematology and clinical chemistry laboratory analyses (e.g. blood, kidney, liver, infections) compared to placebo treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs - Changes from baseline of vital signs (incl. oxygen saturation (spO2), blood pressure, pulse, body weight) compared to placebo treatment</measure>
    <time_frame>14 days</time_frame>
    <description>To investigate the efficacy of NBMI daily oral administration for 14 days on changes from baseline of vital signs (incl. oxygen saturation (spO2), blood pressure, pulse, body weight) compared to placebo treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function FEV - Changes from baseline in pre-, post-bronchodilator and FVC compared to placebo treatment.</measure>
    <time_frame>14 days</time_frame>
    <description>To investigate the efficacy of NBMI daily oral administration for 14 days on lung function in patients with mild, moderate and severe COPD on changes from baseline in pre-, post-bronchodilator and FVC compared to placebo treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function St George - Changes from baseline in St George´s respiratory questionnaire compared to placebo treatment</measure>
    <time_frame>14 days</time_frame>
    <description>To investigate the efficacy of NBMI daily oral administration for 14 days on lung function in patients with mild, moderate and severe COPD on changes from baseline in St George´s respiratory questionnaire compared to placebo treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>COPD</condition>
  <condition>COPD Bronchitis</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>14 days treatment with NBMI 300 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>14 days treatment with Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emeramide</intervention_name>
    <description>Lipophilic, membrane passing Metal chelator and anti oxidant</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>NBMI</other_name>
    <other_name>Irminix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>14 days treatment with placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects, age between 45 and 75 years, including

          2. Ex-smokers, who quit smoking &gt; 6 months prior to screening visit, with a smoking
             history of at least 10 pack years

          3. Diagnosis of COPD according to GOLD stages I-III, i.e. Post-beta-2-agonist FEV1/FVC &lt;
             0.70 and Post-beta-2-agonist FEV1 &gt;30 % of predicted value

          4. Active symptomatic COPD with a total COPD assessment test (CAT) score &gt;10

          5. Bronchitis with cough and sputum production during many days of the last month, and at
             least three months during the last year

          6. Has signed informed consent for participation

          7. Willingness and ability to comply with study procedures, visit schedules, and other
             instructions regarding the study.

        Exclusion Criteria:

          1. Patient with &gt; 2 COPD exacerbation requiring treatment with systemic corticosteroids
             and/or antibiotics or hospitalization within the last year

          2. Patient with COPD exacerbation requiring treatment with systemic corticosteroids
             and/or antibiotics or hospitalization within the last 4 weeks

          3. New medication or change of dose for COPD treatment within 4 weeks prior to
             randomisation (chronic treatment with stable dose is allowed)

          4. Ongoing treatment with systemic steroids, antibiotics, oxygen treatment,
             N-acetylcysteine (NAC) or roflumilast within 4 weeks of randomisation

          5. Clinically significant heart failure, heart infarction, stroke or TIA within 12 months
             of study screening

          6. Ongoing treatment with warfarin at screening visit

          7. Ongoing treatment with medications that are metabolised or eliminated through the CYP
             P450 system, which could cause a drug interaction with the investigational product, as
             judged by the investigator, within 2 weeks of randomisation

          8. Ongoing treatment with metal containing medications, such as iron supplement, lithium
             medications or antacids, within 2 weeks of randomisation

          9. History of alcohol abuse or substance/drug abuse within 12 months prior to screening
             visit

         10. History of any clinically significant disease or disorder which, in the opinion of the
             investigator, may either put the subjects at risk because of participation in the
             study, or influence the results or the subject's ability to participate in the study

         11. Any clinically significant abnormalities in clinical chemistry or haematology results
             at the time of screening, as judged by the investigator

         12. Total alanine aminotransferase (ALT), aspartate aminotransferase (AST) or creatinine &gt;
             upper limit of normal (ULN) at screening

         13. History of severe allergy/hypersensitivity or on-going allergy/hypersensitivity, as
             judged by the investigator, including history of hypersensitivity to drugs with a
             similar chemical structure or class to NBMI

         14. History of allergy/hypersensitivity to bisulphites (e.g. red/white wine)

         15. Women of child bearing potential who do not consent to using acceptable methods of
             contraception (i.e. one of the following: combined hormonal contraception and
             progestogen-
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2017</study_first_submitted>
  <study_first_submitted_qc>April 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <last_update_submitted>April 20, 2017</last_update_submitted>
  <last_update_submitted_qc>April 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Bronchitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

